In the BioHarmony Drug Report Database

"Preview" Icon

Docetaxel

Docefrez, Docetaxel, Taxotere, Docetaxel Winthrop, Docetaxel Zentiva (docetaxel) is a small molecule pharmaceutical. Docetaxel was first approved as Docefrez on 1995-11-27. It is used to treat breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, and ovarian neoplasms amongst others in the USA. It has been approved in Europe to treat adenocarcinoma, breast neoplasms, head and neck neoplasms, non-small-cell lung carcinoma, and prostatic neoplasms amongst others. The pharmaceutical is active against tubulin beta chain. Docetaxel’s patents are valid until 2033-09-30 (FDA).

 

Trade Name

 

Docetaxel Winthrop, Docetaxel Zentiva, Taxotere
 

Common Name

 

docetaxel
 

ChEMBL ID

 

CHEMBL3545252
 

Indication

 

adenocarcinoma, breast neoplasms, head and neck neoplasms, melanoma, non-small-cell lung carcinoma, ovarian neoplasms, pancreatic neoplasms, prostatic neoplasms, soft tissue neoplasms, stomach neoplasms
 

Drug Class

 

Antineoplastics, taxane derivatives

Image (chem structure or protein)

Docetaxel structure rendering